Multicenter Randomized Double-blind Controlled Trial on Efficacy of Lactobacillus gasseri OLL2716 for Helicobacter pylori infection: Impact of probiotics on dyspeptic symptoms
Not Applicable
- Conditions
- H. pylori infection with dyspepsia
- Registration Number
- JPRN-UMIN000016746
- Lead Sponsor
- Study group of LG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
included organic disorders, such as gastric cancer, gastric ulcers, duodenal ulcers, pyloric stenosis, use of NSAIDs, antibiotic treatment before the study, use of PPIs or H2 antagonists, H. pylori eradication therapy within 6 months before the study, ingestion of yogurt or lactic acid bacteria beverages, and the use of antiflatulence agents.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method he urea breath test was performed, and subjects fasted on the day of testing. Serum pepsinogen (PG) was measured and H. pylori stool antigen detection was evaluated. UBT, serum pepsinogen, and stool antigen detection were performed before and after consumption of the test product.
- Secondary Outcome Measures
Name Time Method Gastrointestinal symptoms were assessed using a visual analogue scale (VAS). Each participant kept a diary during consumption of the test product to record compliance and gastrointestinal symptoms (upper abdominal pain, bloating, indigestion, nausea, vomiting, and heartburn).